A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)

Trial Profile

A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Tarextumab (Primary) ; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PINNACLE
  • Sponsors OncoMed Pharmaceuticals
  • Most Recent Events

    • 17 Apr 2017 According to an OncoMed Pharmaceuticals media release, company plans to present full study findings, including results from the biomarker analyses from this trial at a future scientific conference.
    • 17 Apr 2017 Top-line results published in an OncoMed Pharmaceuticals the Media Release.
    • 17 Apr 2017 Status changed from active, no longer recruiting to completed, according to an OncoMed Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top